| . | ‘�މ–b | –O˜aމ–b | ƒgƒ‰ƒ“ƒXމ–b | ƒRƒŒƒXƒeƒ��[ƒ‹ |
| �¢ŠE•ÛŒ’‹@�\WHO‚Ì–Ú•W—Ê | 15-30% | 10%–¢–ž | 1%–¢–ž | 300mg/“ú–¢–ž |
| •Ä�‘�S‘Ÿ‹¦‰ïAHA‘å�l‚Ì–Ú•W—Ê | . | 7%–¢–ž | 1%–¢–ž | 300mg/“ú–¢–ž |
| •Ä�‘�S‘Ÿ‹¦‰ïAHA4-18�΂̖ڕW—Ê | 25-35% | �‚È‚ | �‚È‚ | . |
| •Ä�‘Šw�Z‹‹�H‚ÌŠî�€ | 30%ˆÈ‰º | 10%–¢–ž | . | �‚È‚ |
| ‰p�‘Šw�Z‹‹�H‚ÌŠî�€ | 35%ˆÈ‰º | 11%ˆÈ‰º | 2%ˆÈ‰º | . |
| “ú–{�l‚Ì�HŽ–�ÛŽæŠî�€ | . | . | . | . |
| 30-69�Î�@’j�« | 20-25% | 4.5-7.0% | . | 750mg/“ú–¢–ž |
| 30-69�Î�@�—�« | 20-25% | 4.5-7.0% | . | 600mg/“ú–¢–ž |
| 18-29�Î�@’j�« | 20-30% | 4.5-7.0% | . | 750mg/“ú–¢–ž |
| 18-29�Î�@�—�« | 20-30 | 4.5-7.0% | . | 600mg/“ú–¢–ž |
| 6-17�Î ’j�« | 20-30% | . | . | . |
| 6-17�Î �—�« | 20-30% | . | . | . |
| “Œ‹ž“sŠw�Z‹‹�H‚ÌŠî�€ | 25-30% | . | . | . |